ArticleResearch and practice in thrombosis and haemostasis2026
Eltrombopag use in surgical procedures in inherited thrombocytopenia: expanding the role of thrombopoietin-receptor agonists.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombopoietin receptor agonists in inherited thrombocytopenias: an evolving mosaic of evidence.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inherited thrombocytopenias (ITs) are a group of rare disorders characterized by low platelet counts and variable bleeding risk. Surgical procedures in these patients often require transient platelet elevation. Thrombopoietin-receptor agonists, such as eltrombopag, offer a potential alternative to platelet transfusions, which carry risks including alloimmunization and refractoriness. Objectives: To evaluate the efficacy and safety of short-term eltrombopag administration in patients with ITs undergoing elective surgical procedures. Methods: Nine patients with confirmed ITs (MYH9-related disease, ANKRD26-related thrombocytopenia [-RT], ITGA2B/ITGB3-RT, ACTN1-RT) underwent 15 surgical procedures. Eltrombopag was administered at 50 mg/d, initiated approximately 3 weeks prior to surgery. Platelet counts, bleeding complications, and adverse events were monitored. Results: A favorable platelet response occurred in 14 of 15 procedures. Major response criteria-platelet count ≥100 × 10 Conclusion: Short-term eltrombopag administration was effective in increasing platelet counts and preventing bleeding complications in patients with IT undergoing surgery. The inclusion of the first reports of ACTN1-RT expands the therapeutic scope of thrombopoietin-receptor agonists. Although larger studies remain challenging due to the rarity of these conditions, our results contribute meaningful clinical evidence to guide perioperative management in IT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.